BiomX, Inc.
BiomX is a clinical-stage biotechnology company developing natural and engineered phage cocktails and personalized treatments to target and destroy harmful bacteria in chronic diseases. The company focuses on innovative medicines for conditions such as cystic fibrosis, diabetic foot osteomyelitis, and other bacterial infections, leveraging proprietary bacterial targets and phage compositions. BiomX collaborates with leading scientific institutions and pharmaceutical companies to advance its pipeline of phage therapies.
Industries
Nr. of Employees
medium (51-250)
BiomX, Inc.
708 Quince Orchard Rd, Suite 205, Gaithersburg, MD 20878, USA
Products
Phage therapy candidate for chronic Pseudomonas aeruginosa respiratory infections (BX004)
An investigational bacteriophage therapy candidate developed to reduce or eradicate chronic Pseudomonas aeruginosa in respiratory infections; evaluated in clinical studies for cystic fibrosis and being explored for non-CF bronchiectasis.
Phage therapy candidate for diabetic foot osteomyelitis and infections (BX211)
An investigational bacteriophage therapy candidate targeting Staphylococcus aureus associated with diabetic foot infections and osteomyelitis; evaluated in clinical trials for reduction of chronic bone and soft-tissue infections.
Orally delivered phage candidate for Klebsiella-associated gut disease (BX003, preclinical)
Phage candidates identified with broad host range against Klebsiella pneumoniae strains, evaluated in vitro and in vivo models for potential oral administration to reduce target gut bacteria associated with inflammatory and liver diseases.
Phage therapy candidate for chronic Pseudomonas aeruginosa respiratory infections (BX004)
An investigational bacteriophage therapy candidate developed to reduce or eradicate chronic Pseudomonas aeruginosa in respiratory infections; evaluated in clinical studies for cystic fibrosis and being explored for non-CF bronchiectasis.
Phage therapy candidate for diabetic foot osteomyelitis and infections (BX211)
An investigational bacteriophage therapy candidate targeting Staphylococcus aureus associated with diabetic foot infections and osteomyelitis; evaluated in clinical trials for reduction of chronic bone and soft-tissue infections.
Orally delivered phage candidate for Klebsiella-associated gut disease (BX003, preclinical)
Phage candidates identified with broad host range against Klebsiella pneumoniae strains, evaluated in vitro and in vivo models for potential oral administration to reduce target gut bacteria associated with inflammatory and liver diseases.
Services
Design and execution of multi-phase clinical studies for investigational phage therapies, including enrollment, treatment delivery, monitoring and data collection.
Assessment and potential provision of investigational phage products to individual patients via local regulatory mechanisms, following a structured review by medical experts.
Metagenomics-based biomarker discovery to identify microbial signatures for patient stratification and responder identification in inflammatory and other diseases.
High-throughput and targeted screening of phage activity against clinical isolate libraries and selection of broad-host-range candidates for development.
Structuring and managing collaborative research agreements, licensing options and strategic partnerships with pharmaceutical companies and regional licensees.
Design and execution of multi-phase clinical studies for investigational phage therapies, including enrollment, treatment delivery, monitoring and data collection.
Assessment and potential provision of investigational phage products to individual patients via local regulatory mechanisms, following a structured review by medical experts.
Metagenomics-based biomarker discovery to identify microbial signatures for patient stratification and responder identification in inflammatory and other diseases.
High-throughput and targeted screening of phage activity against clinical isolate libraries and selection of broad-host-range candidates for development.
Structuring and managing collaborative research agreements, licensing options and strategic partnerships with pharmaceutical companies and regional licensees.
Expertise Areas
- Phage therapeutics development
- Microbiome and metagenomic biomarker discovery
- Preclinical infectious-disease modeling and screening
- Clinical trial management for antimicrobial biologics
Key Technologies
- Bacteriophage discovery and engineering
- Metagenomic sequencing and microbial genomic signatures
- In vitro biofilm assays
- In vivo infectious disease models
News & Updates
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates